✦Canada Post Xpress1–2 day delivery across CanadaFree on orders over $200
Your cart is empty
GHRH Analogue Research Peptide
CJC-1295 (No DAC) is commonly studied for its role in stimulating short-acting growth hormone signaling and mimicking natural pulsatile GH release patterns in research models. It is often explored for its effects on recovery processes, tissue maintenance, and metabolic regulation within controlled laboratory settings.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
CJC-1295 (No DAC) is a synthetic peptide analogue of growth hormone–releasing hormone (GHRH) developed for controlled laboratory research. The “No DAC” designation indicates the absence of a drug affinity complex, resulting in a shorter receptor interaction profile within experimental systems.
In scientific literature, CJC-1295 (No DAC) is studied in models examining GHRH receptor activation, hypothalamic-pituitary signaling pathways, and downstream endocrine regulatory mechanisms under in vitro and preclinical research conditions.
Third-party tested for purity, identity, quantity.
CJC-1295 (No DAC) is a modified GHRH analogue evaluated in research focused on growth hormone–releasing hormone receptor activity and endocrine signaling systems. Experimental studies examine receptor-binding dynamics, hypothalamic-pituitary axis interaction models, and regulated peptide signaling pathways within controlled laboratory environments.
Research publications have explored its receptor interaction profile and downstream growth hormone–associated signaling mechanisms under structured study conditions.
CJC-1295 was developed during investigations into stabilized GHRH analogues designed to enhance receptor interaction and signaling characteristics. Variants were created with and without a drug affinity complex (DAC), allowing comparative study of duration and receptor interaction properties.
Subsequent research documented its signaling profile within endocrine pathway research frameworks.
Laboratory investigations into CJC-1295 (No DAC) have focused on GHRH receptor activation models and downstream endocrine signaling pathways. Research frameworks evaluate receptor-mediated interaction, hypothalamic-pituitary axis dynamics, and regulated peptide response systems under controlled in vitro and preclinical conditions.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 10mg of lyophilized CJC-1295 (No DAC). Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the peptide preparation. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone–releasing hormone, in healthy adults.
PubMedRelated
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$180.00
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$10.00
Immune-modulating peptide studied for T-cell signaling and immune system regulatory pathway research
From$70.00
GHRH analog studied for growth hormone regulation and metabolic pathway signaling research
From$95.00
